Navigation Links
Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
Date:1/11/2010

SAN DIEGO, Jan. 11 /PRNewswire/ -- Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the 28th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for 2:00 p.m. PST on Thursday, January 14, at the Westin St. Francis in San Francisco, Calif. The J.P. Morgan Healthcare Conference is one of the largest and most informative healthcare investment symposiums in the industry. Over 300 public and private companies are expected to present at the conference.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
2. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
3. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
4. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
5. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Poniard Pharmaceuticals Announces $6.5 Million Financing
8. Titan Pharmaceuticals to Receive $3 Million Loan
9. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
10. Lotus Pharmaceuticals, Inc. Appoints OTC Division Head
11. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... bioLytical Laboratories Inc. announced ... was accepted for presentation at the 8th Annual International AIDS Society (IAS) Conference ... Wednesday, July 22nd from 1:00 pm to 2:00pm Pacific Standard Time at the ...
(Date:7/7/2015)... ... , ... uBiome, the leading microbial genomics company, is offering talented researchers with ... 16S laboratory analysis. The goal is to fast-track a study with the greatest potential ... own dashboard, enabling them to view and compare the results of their study, as ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Pistoia ... to innovation in life science R&D, has attracted a number of new members ... top ten pharmaceutical company joining as a Core member, and DNAnexus and Tessella ...
(Date:7/6/2015)... 6, 2015  Emdeon Inc. today announced ... agreement to acquire Altegra Health, a national ... combine data aggregation and analytics with unique ... actionable insights and improved management for value-based ... risk adjustment and quality analytics and Emdeon,s ...
Breaking Biology Technology:bioLytical to Present Findings of Early HIV Detection 2bioLytical to Present Findings of Early HIV Detection 3uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 3Pistoia Alliance Continues to Attract New Members 2Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4
... , NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. ... Officer of BioMarin, will present a company update at the Morgan Stanley ... 1:35 p.m. ET. , , Interested parties ... investor section of the BioMarin website, www.BMRN.com . ...
... , SAN DIEGO, Sept. 8 eBioscience Corporation, a ... the acquisition of NatuTec GmbH, a leading distributor of high-quality biological ... , "For the past 10 years, NatuTec has ... R. Nelson, CEO of eBioscience. "The NatuTec acquisition provides eBioscience ...
... LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- ... a,U.S. pharmaceutical company with its principal operations in the ... for,fiscal year 2009. The Company expects to meet ... revenue and operating income of $40 to $43 million ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Healthcare Conference 2eBioscience Corporation Acquires NatuTec GmbH 2Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 2
(Date:7/2/2015)... 2, 2015 Fingerprint Cards has received ... and FPC1155 from the distributor World Peace Industrial Group (WPI), ... in Asia . Deliveries are planned to ... be used by smartphone manufacturers in Asia ... the communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... in the Southampton Centre for Biomedical Research, established ... (SUHT) and the University of Southampton, have been ... and respiratory research facilities. The funding, ... investment in NHS and university partnerships, has secured ...
... of celiac disease in women who present with unexplained ... The Journal of Reproductive Medicine, the study ... participant underwent serologic screening for celiac disease as well ... had positive serum test results were advised to seek ...
... of revising now that biologists at UC San Diego have ... According to the textbooks, chromatin, the natural state of DNA ... nucleosomes are the basic repeating unit of chromatin. When ... on a string (photo at right). But in the August ...
Cached Biology News:Southampton researchers awarded $28 million to progress pioneering nutrition and respiratory research 2Biologists' discovery may force revision of biology textbooks 2
...
Rubeola (Measles) Antigen Preservative: No Preservatives...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Homo sapiens jumping translocation breakpoint...
Biology Products: